Eli Lilly's (LLY) jaypirca significantly continued progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

Eli Lilly's latest trial results indicate a significant improvement in progression-free survival for their drug Jaypirca when combined with Venetoclax in patients with previously treated CLL/SLL.

Newsquawk StaffPublished 13 Apr 2026, 11:05 UTCOn the live feed at 10:45 UTC — 5 more headlines followed before this page went public

Newsquawk headlinesUTC

10:52

"Israeli airstrike on the town of Al-Sama'iyah in southern Lebanon", Sky News Arabia reports

10:49

Fastenal Company (FAST) Q1 2026 (USD): EPS 0.30 (exp. 0.30), Revenue 2.2bln (exp. 2.20bln)

10:45

Eli Lilly's (LLY) jaypirca significantly continued progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

10:44

YPF awards Halliburton (HAL) multibillion-dollar long-term unconventional completions contract in Argentina

10:41

EU Commission President von der Leyen says the EU's bill for fossil fuels has increased by EUR 22bln since the start of the Iran war, a robust coordination between member states for energy prices is needed

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm.

Context

This Phase 3 readout not only outperforms existing treatments but also suggests potential market momentum for LLY, reinforcing its competitive position in the pharmaceuticals sector. Investors will be keen to assess the implications for future revenue growth and pricing strategies as this could bolster Eli Lilly's profile in oncology.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

Modest downside seen across equity futures as energy prices tick higher.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

EQUITIES/26 Aug · 12:56 UTC

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

EQUITIES/7 Sept · 10:54 UTC

Saudi Aramco Jizan oil facilities were reportedly hit in new strikes, the FT reports citing sources; hit on Monday, damage is being assessed.

Equity indices, after we published−0.1%

EQUITIES/7 Sept · 09:15 UTC

Volkswagen (VOW3 GY) says that the Co., Lower Saxony and Aurelius Capital have agreed on key terms for the sale of Osnabrueck Plant; aims to secure the site and majority of jobs in the long term.

Market, after we published+1.6%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.